Bortezomib in Patients with Metastatic Castration-Resistant Prostate Cancer with PTEN Deletion

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 11, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2028

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

Bortezomib

sub-cutaneous injection of bortezomib for 6-8 cycles of treatment.

Trial Locations (1)

RECRUITING

Huntsman Cancer Institute/University of Utah, Salt Lake City

All Listed Sponsors

lead

University of Utah

OTHER